Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| NREF | PRESS-RELEASE | mixed | 6/10 | NREF reported Q2 2026 EAD of $0.46 per share, beating the $0.40 consensus by 15%, but guided Q3 2026 EAD to a midpoint o | Aug 6, 2026 |
| APT | PRESS-RELEASE | neutral | 4/10 | Alpha Pro Tech reported Q2 2026 results with net sales up 12.0% YoY to $18.7M and net income up 46.8% to $1.8M ($0.18 di | Aug 6, 2026 |
| DTST | PRESS-RELEASE | neutral | 1/10 | Data Storage Corp. announced it will host a conference call on August 14, 2026 to discuss its Q2 2026 results. | Aug 6, 2026 |
| DARE | PRESS-RELEASE | neutral | 1/10 | Daré Bioscience, Inc. announced it will host a conference call on August 13, 2026 to discuss its Q2 2026 results. | Aug 6, 2026 |
| ZS | PRESS-RELEASE | neutral | 1/10 | Zscaler, Inc. announced it will host a conference call on September 3, 2026 to discuss its fiscal Q4 2026 results. | Aug 6, 2026 |
| CMPX | PRESS-RELEASE | bullish | 7/10 | Compass Therapeutics reported Q2 2026 net loss of $25.2M ($0.13/share), wider than the $19.9M loss in Q2 2025, driven by | Aug 6, 2026 |
| LXRX | PRESS-RELEASE | neutral | 5/10 | Lexicon Pharmaceuticals reported Q2 2026 revenue of $0.7M, down 97.6% from $28.9M a year ago due to the absence of a $27 | Aug 6, 2026 |
| KELYA | PRESS-RELEASE | mixed | 6/10 | Kelly Services Q2 2026 adjusted EPS of $0.37 beat the $0.23 consensus by 57.4%, though GAAP EPS fell 40% YoY to $0.31. R | Aug 6, 2026 |
| CRON | PRESS-RELEASE | mixed | 6/10 | Cronos Group reported Q2 2026 results with record net revenue of $53.0M (+58% YoY) and record gross profit of $28.5M (+9 | Aug 6, 2026 |
| SUNS | PRESS-RELEASE | bearish | 5/10 | Sunrise Realty Trust reported Q2 2026 Distributable Earnings of $0.29 per share, a 4.8% beat vs. $0.27 consensus, but do | Aug 6, 2026 |
| AMTX | PRESS-RELEASE | bearish | 7/10 | Aemetis reported Q2 2026 revenue of $62.7M, up 20% YoY, and operating income of $5.8M versus a $10.7M loss a year ago, d | Aug 6, 2026 |
| FNF | PRESS-RELEASE | neutral | 4/10 | FNF reported Q2 2026 EPS of $1.39, beating consensus of $1.32 by 5.4%. Revenue was $3.79B, in line with estimates. The b | Aug 6, 2026 |
| WTM | PRESS-RELEASE | neutral | 4/10 | White Mountains reported Q2 2026 book value per share of $2,258, up 4% for the quarter, driven by strong underwriting at | Aug 6, 2026 |
| ADCT | PRESS-RELEASE | neutral | 1/10 | ADC Therapeutics SA announced it will host a conference call on August 13, 2026 to discuss its Q2 2026 results. | Aug 6, 2026 |
| SRE | PRESS-RELEASE | neutral | 5/10 | No summary provided | Aug 6, 2026 |
| SABR | PRESS-RELEASE | bullish | 7/10 | Sabre Corporation reported Q2 2026 revenue of $712M (+4% YoY) and EPS of $0.06, significantly beating consensus estimate | Aug 6, 2026 |
| CMND | PRESS-RELEASE | bullish | 6/10 | Clearmind Medicine received unanimous DSMB approval to advance its Phase I/II trial of CMND-100 for Alcohol Use Disorder | Aug 6, 2026 |
| ANNX | PRESS-RELEASE | bullish | 7/10 | Annexon announced early positive data from the FORWARD open-label study of tanruprubart in Guillain-Barré syndrome (GBS) | Aug 6, 2026 |
| PCRX | PRESS-RELEASE | bullish | 6/10 | Pacira BioSciences reported positive two-year Phase 1 data for PCRX-201, a gene therapy for knee osteoarthritis, publish | Aug 6, 2026 |
| ASND | PRESS-RELEASE | bullish | 7/10 | Ascendis Pharma released positive Phase 2 COACH trial data showing its TransCon CNP + TransCon hGH combination therapy m | Aug 6, 2026 |
| ARGX | PRESS-RELEASE | bullish | 7/10 | argenx has commenced a tender offer to acquire all outstanding shares of Forte Biosciences for $77.00 per share in cash, | Aug 6, 2026 |
| WBD | PRESS-RELEASE | bullish | 7/10 | The UK Competition and Markets Authority (CMA) has formally cleared Paramount Skydance Corporation's acquisition of Warn | Aug 6, 2026 |
| PHVS | PRESS-RELEASE | neutral | 4/10 | Pharvaris announced publication of the first in-depth qualitative study in AAE-C1INH in Frontiers in Immunology, validat | Aug 6, 2026 |
| TARS | PRESS-RELEASE | neutral | 6/10 | Tarsus acquires Alkeus Pharmaceuticals for $450M upfront plus up to $350M in milestones, adding the Phase 3 Stargardt di | Aug 6, 2026 |
| LAMR | PRESS-RELEASE | bullish | 6/10 | Lamar Advertising reported Q2 2026 results with net revenues of $616.7M (+6.5% YoY) and AFFO per share of $2.40, beating | Aug 6, 2026 |
| GCT | PRESS-RELEASE | bullish | 5/10 | GigaCloud Technology reported Q2 2026 revenue of $411.6M (+27.6% YoY) and diluted EPS of $1.16 (+27.5% YoY), both record | Aug 6, 2026 |
| PBH | PRESS-RELEASE | bullish | 6/10 | Prestige Consumer Healthcare reported Q1 FY2027 revenue of $265.7M (+6.5% YoY) and adjusted diluted EPS of $0.98 (+3.2% | Aug 6, 2026 |
| TSQ | PRESS-RELEASE | mixed | 6/10 | Townsquare Media reported Q2 2026 GAAP EPS of -$2.36, a massive miss vs the $0.19 consensus, driven by a $26.6M non-cash | Aug 6, 2026 |
| ARHS | PRESS-RELEASE | neutral | 5/10 | Arhaus reported Q2 2026 revenue of $385M (+7.4% YoY), beating consensus of $365.6M, and EPS of $0.28, beating the $0.16 | Aug 6, 2026 |
| MFIC | PRESS-RELEASE | mixed | 5/10 | MidCap Financial Investment Corporation (MFIC) reported Q2 2026 NII per share of $0.40, beating consensus of $0.36 by 11 | Aug 6, 2026 |